# Divi's Laboratories (DIVISLAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/divislab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹10,320.5
- Change: +1.78%
- As of: 2026-11-06
- 1D return: +1.78%
- 5D return: +5.53%
- 1M return: +10.25%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

DIVISLAB exhibits a strong, established uptrend across daily, weekly, and monthly timeframes as of November 6, 2026. The stock closed at ₹10,320.50, trading near its recent highs with all major moving averages and the Supertrend indicator confirming bullish alignment. Trend strength is robust on the weekly horizon (ADX 43.83) and established on the daily (ADX 27.37), supported by positive directional indicators (+DI significantly above -DI). Price positioning is at the upper extreme of both the 20-day and 252-day ranges (+100%), indicating limited immediate upside room but strong momentum. Recent activity includes a moderate upward gap on November 2 and an unusual price move on October 27. Risk metrics show annualized volatility at +26.0% and a maximum drawdown of -18.5%. Key levels to monitor include resistance at ₹10,333.50 and support at ₹10,237.00.

- Trend Direction: Bullish across all timeframes; price trades above all supplied moving averages and the Supertrend indicator.
- Momentum & Strength: Weekly ADX is 43.83 (strong); Daily ADX is 27.37 (established). +DI (34.25) dominates -DI (11.96) on the daily chart.
- Price Positioning: Current price ₹10,320.50 is at the top of the 20-day, 50-day, and 252-day ranges (+100%).
- Key Levels: Immediate resistance at ₹10,333.50 (+0.13%); nearest support at ₹10,237.00 (-0.81%) and pivot at ₹10,062.50 (-2.50%).
- Risk Profile: Annualized volatility is +26.0%; current drawdown is +0.0%.

- Hammer
- Outside Bar
- Harami
- Bullish Engulfing Reversal
- Inside Bar

### News Context

Divi's Laboratories (NSE: DIVISLAB) has scheduled its Board of Directors meeting for November 7, 2026, to approve unaudited financial results for the half-year ended September 30, 2026. The subsequent Q2 FY2027 earnings conference call is set for the same day at 14:00 IST. As of the market close on November 6, 2026, the stock traded at ₹10,320.50, reflecting a year-to-date return of +62.7% and a six-month return of +54.0%. Technical indicators across daily, weekly, and monthly timeframes show a bullish Supertrend direction, with the price currently testing immediate resistance near ₹10,333.50. Shareholding data as of September 30, 2026, indicates promoters hold 51.88% of the equity, while the public holds 48.12%.

- Catalyst: Board meeting on November 7, 2026, to approve H1 FY2027 results; earnings call follows at 14:00 IST.
- Price Action: Stock closed at ₹10,320.50 on November 6, up +1.8% from the previous close, with strong YTD (+62.7%) and 6M (+54.0%) performance.
- Technical Setup: Daily, weekly, and monthly trends are bullish; immediate resistance sits at ₹10,333.50 (0.13% above current price).
- Ownership Structure: Promoters held 51.88% stake as of September 30, 2026, against public holding of 48.12%.

- Divi's Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation
- Board Meeting Intimation |Meeting Date: 07-Nov-2026
- Financial Results |Meeting Date: 07-Nov-2026
- AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 51.88 | PUBLIC_VAL: 48.12 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 06-Oct-2026 | REVISION_DT: -

### Official Filings

Divi's Laboratories Limited has scheduled its Board of Directors meeting for November 7, 2026, to approve unaudited financial results for the half-year and quarter ended September 30, 2026. The subsequent earnings conference call is set for November 7, 2026, at 14:00 IST. Shareholding data as of September 30, 2026, indicates that public holding stands at 48.12%. Additionally, the company closed its trading window on September 30, 2026, in compliance with insider trading regulations ahead of the results announcement.

- Board Meeting Date: November 7, 2026, to consider Q2 and H1 FY2027 unaudited financial results.
- Earnings Call: Scheduled for November 7, 2026, at 14:00 IST; contact person is Mr. M. Satish Choudhury.
- Shareholding Pattern (as of Sep 30, 2026): Public holding at 48.12%; Promoter/Group holding at 51.88%.
- Trading Window Closure: Effective September 30, 2026, pursuant to SEBI (Prohibition of Insider Trading) Regulations.

- [Divi's Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20261102_085031816.xml)
- [Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Board Meeting Intimation |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Financial Results |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/DIVISLAB_22102026170023_Intimation_BoardMeeting_07112026.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 51.88 | PUBLIC_VAL: 48.12 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 06-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733233_06102026103802_WEB.xml)
- [Divi's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/DIVISLAB_06102026122638_Reg_74_5_.pdf)
- [Divi's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |SUBJECT: Trading Window](https://nsearchives.nseindia.com/corporate/DIVISLAB_30092026093952_Intimation_TradingWindowClosure_Q2FY27.pdf)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094419784.xml)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094444838.xml)
- [Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/DIVISLAB_12092026115855_Special_Window_PaperAdv.pdf)

### Fundamentals

Divi's Laboratories reported a sequential decline in Q1 FY2026-27, with revenue from operations falling to ₹3,080 crore and net profit dropping to ₹902 crore, compared to ₹10,560 crore and ₹2,568 crore respectively in the preceding quarter (Q4 FY2025-26). This quarterly contraction contrasts sharply with the company’s longer-term trajectory: TTM sales have grown 16% and TTM net profit has surged 29%, while ROCE improved to 22% in Mar 2026. The balance sheet shows significant expansion in Fixed Assets (₹6,528 crore) and CWIP (₹2,113 crore), indicating ongoing capacity addition, supported by strong operating cash flows of ₹2,738 crore in Mar 2026. However, interest costs rose materially to ₹24 crore in Mar 2026 from ₹3 crore previously, reflecting increased borrowings. While earnings quality remains high with CFO/EBITDA conversion at 105% in Mar 2026, the sharp sequential drop in Q1 FY26-27 warrants monitoring for seasonality or temporary demand softness.

- Sequential Q1 FY26-27 weakness: Revenue fell to ₹3,080 crore and net profit to ₹902 crore from ₹10,560 crore and ₹2,568 crore in Q4 FY25-26.
- Strong TTM growth persists: Sales grew 16% and net profit grew 29% on a trailing twelve-month basis, with ROCE rising to 22%.
- Balance sheet expansion: Fixed assets reached ₹6,528 crore and CWIP jumped to ₹2,113 crore; borrowings increased to ₹7 crore, raising interest costs to ₹24 crore.
- Cash flow resilience: Operating cash flow stood at ₹2,738 crore in Mar 2026 with 105% conversion, offsetting investing outflows of ₹2,219 crore.

### Bull Case

Divi's Laboratories exhibits strong technical momentum across multiple timeframes as of November 6, 2026. The stock is trading at ₹10,320.50, supported by a bullish Supertrend signal on both daily and monthly charts. Technical indicators show significant buying pressure, with the Plus DI (34.25) substantially exceeding the Minus DI (11.96) on the daily timeframe, while the Average Directional Index (ADX) of 27.37 suggests a developing trend rather than choppy movement. This structural strength is corroborated by robust recent performance: the stock has gained +62.7% year-to-date and +54.0% over the last six months. A key condition for this constructive view is the ability to hold above immediate support levels; the nearest high-based support sits at ₹10,237.00, just 0.81% below the current price. If the stock maintains its position above this threshold, the prevailing trend structure remains intact.

- Multi-timeframe bullish structure confirmed by Supertrend signals on daily and monthly charts as of 2026-11-06.
- Strong directional bias indicated by Daily Plus DI (34.25) significantly higher than Minus DI (11.96).
- Robust recent returns include +62.7% YTD and +54.0% over the past six months.
- Immediate monitoring level is the high-based support at ₹10,237.00 (0.81% below current price).

- [Divi's Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20261102_085031816.xml)
- [Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Board Meeting Intimation |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Financial Results |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/DIVISLAB_22102026170023_Intimation_BoardMeeting_07112026.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 51.88 | PUBLIC_VAL: 48.12 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 06-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733233_06102026103802_WEB.xml)
- [Divi's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/DIVISLAB_06102026122638_Reg_74_5_.pdf)
- [Divi's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |SUBJECT: Trading Window](https://nsearchives.nseindia.com/corporate/DIVISLAB_30092026093952_Intimation_TradingWindowClosure_Q2FY27.pdf)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094419784.xml)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094444838.xml)
- [Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/DIVISLAB_12092026115855_Special_Window_PaperAdv.pdf)

### FAQs

**When will Divi's Laboratories release its Q2 FY2027 financial results?**

The Board of Directors is scheduled to meet on November 7, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The subsequent earnings conference call will be held virtually on the same day, November 7, 2026, commencing at 14:00 IST.

**What is the current shareholding pattern as of the latest disclosure?**

As of September 30, 2026, Public holding stands at 48.12%, while Promoter and Promoter Group (P&PRGRP) holding is 51.88%. Employee holding is reported at 0%. This data was submitted to the exchange on October 6, 2026.

**How has the stock performed over key timeframes recently?**

As of November 6, 2026, DIVISLAB has delivered a year-to-date return of +62.7% and a one-year return of +49.9%. Over the last six months, the return is +54.0%, with a three-month return of +23.6%. The stock closed at ₹10,320.50 on this date.

**What are the immediate technical support and resistance levels?**

On a daily basis, the nearest resistance level is at ₹10,333.50 (0.13% above current price), followed by ₹10,508.00 (1.82% above). Key support levels are located at ₹10,237.00 (0.81% below), ₹10,062.50 (2.50% below), and ₹9,966.00 (3.43% below).

- [Divi's Laboratories Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20261102_085031816.xml)
- [Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Board Meeting Intimation |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- [Financial Results |Meeting Date: 07-Nov-2026](https://nsearchives.nseindia.com/corporate/DIVISLAB_22102026170023_Intimation_BoardMeeting_07112026.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 51.88 | PUBLIC_VAL: 48.12 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 06-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733233_06102026103802_WEB.xml)
- [Divi's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/DIVISLAB_06102026122638_Reg_74_5_.pdf)
- [Divi's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |SUBJECT: Trading Window](https://nsearchives.nseindia.com/corporate/DIVISLAB_30092026093952_Intimation_TradingWindowClosure_Q2FY27.pdf)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094419784.xml)
- [Divi's Laboratories Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094444838.xml)
- [Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/DIVISLAB_12092026115855_Special_Window_PaperAdv.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹10,062.5
- Risk regime: Price Risk Currently Contained

### Support levels
- 9318
- 9078
- 8863.625

### Resistance levels
- 10508

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.78% |
| return_10 | +15.31% |
| return_1m | +8.07% |
| return_1y | +49.93% |
| return_20 | +10.25% |
| return_3m | +23.61% |
| return_5 | +5.53% |
| return_6m | +53.99% |
| return_since_start | +69.94% |
| return_ytd | +62.68% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.53% |
| annualized_volatility | +25.97% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Divi's Laboratories Limited Q2 FY2026-27: Revenue rises 19% sequentially

Revenue from operations increased 19.4% quarter on quarter to ₹3,676 crore in Q2 FY2026-27, while profit before tax rose 27.5% to ₹1,505 crore. Year on year, revenue grew 35.4% and profit after tax increased 63.6% to ₹1,127 crore.

## Revenue and profit growth

Revenue from operations rose for a fourth consecutive quarter, from ₹2,604 crore in Q3 FY2025-26 to ₹3,676 crore in Q2 FY2026-27. Total income was ₹3,770 crore, including ₹94 crore of other income.

Expenses increased 15.3% quarter on quarter to ₹2,265 crore, below the pace of revenue growth. Profit before tax advanced from ₹1,180 crore in Q1 FY2026-27 to ₹1,505 crore. Profit after tax rose from ₹902 crore to ₹1,127 crore, while tax expense increased to ₹378 crore from ₹278 crore. Earnings per share was ₹42.49, up from ₹33.95 in Q1.

## Expense composition

Q2 expenses included ₹1,812 crore of materials consumed and a negative ₹631 crore change in inventories of finished goods, work in progress and stock in trade. Employee benefit expense was ₹444 crore and depreciation and amortisation expense was ₹142 crore. Other expenses rose 12.5% quarter on quarter to ₹485 crore. Finance costs increased to ₹13 crore from ₹6 crore, remaining small relative to total expenses.

## Cash flows and balance sheet

Operating cash flow was ₹384 crore in the quarter, investing cash flow was ₹596 crore and financing cash flow was negative ₹805 crore. Reported free cash flow was ₹980 crore. Cash and cash equivalents stood at ₹303 crore on 30 September 2026, compared with ₹128 crore on 31 March 2026; other bank balances declined to ₹1,933 crore from ₹3,286 crore over the same period.

Inventories rose to ₹5,540 crore on 30 September 2026 from ₹3,954 crore on 31 March 2026 and ₹3,433 crore on 30 September 2025. Trade receivables increased to ₹3,487 crore from ₹2,984 crore at 31 March 2026. Property, plant and equipment stood at ₹7,452 crore, up from ₹6,515 crore, while capital work in progress declined to ₹1,638 crore from ₹2,113 crore. Equity increased to ₹17,997 crore from ₹16,761 crore at 31 March 2026.

## Key Takeaway

Q2 combined strong sequential revenue growth with faster growth in profit before tax, as reported expenses rose more slowly than revenue. The increase in inventories and receivables, alongside lower other bank balances, is an important balance-sheet counterpart to the stronger earnings.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +51.88%
- FII holding: +20.19%
- DII holding: +19.29%
- Mutual fund holding: +13.87%
- Retail holding: +5.93%
- Promoter pledged: +0.00%

### Major reported shareholders

- SATCHANDRA KIRAN DIVI — +20.34%
- NILIMA PRASAD DIVI — +20.34%
- SWARNA LATHA DIVI — +5.27%
- SBI MUTUAL FUND — +3.90%
- GOVERNMENT OF SINGAPORE — +3.64%
- DIVI'S BIOTECH PRIVATE LIMITED — +3.01% (Bodies Corporate)
- MURALI KRISHNA PRASAD DIVI — +2.85%
- Life Insurance Corporation of India — +2.53%
- HDFC MUTUAL FUND — +2.07%
- AXIS MUTUAL FUND TRUSTEE LIMITED — +1.38%

## Official filings

- 2026-11-07 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_07112026115520_Outcome_BoardMeeting_07112026_DivisLabs.pdf)
- 2026-11-07 — Financial Results Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755422_07112026045152_WEB.xml)
- 2026-11-07 — Financial Results Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755425_07112026045655_WEB.xml)
- 2026-11-07 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20261107_171527313.xml)
- 2026-11-02 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20261102_085031816.xml)
- 2026-10-22 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- 2026-10-22 — Board Meeting Notice: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_2132_WebXMLFile_20261022_165829955.xml)
- 2026-10-22 — Board Meeting Notice: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_22102026170023_Intimation_BoardMeeting_07112026.pdf)
- 2026-10-06 — Shareholding Disclosure: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733233_06102026103802_WEB.xml)
- 2026-10-06 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_06102026122638_Reg_74_5_.pdf)
- 2026-09-30 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_30092026093952_Intimation_TradingWindowClosure_Q2FY27.pdf)
- 2026-09-30 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094419784.xml)
- 2026-09-30 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_2132_WebXMLFile_20260930_094444838.xml)
- 2026-09-12 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_12092026115855_Special_Window_PaperAdv.pdf)
- 2026-08-31 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260831_110842619.xml)
- 2026-08-28 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260828_112328721.xml)
- 2026-08-21 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260821_111254441.xml)
- 2026-08-06 — Generic Announcement: Divi's Laboratories Limited held an earnings conference call on August 1, 2026, to discuss results for the quarter ended June 30, 2026. The company reported consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores for Q1 FY27. Management discussed progress on custom synthesis projects, peptide business expansion, and the role of Unit 3 in their manufacturing network. Challenges related to solvent costs and global logistics were also addressed. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_06082026142802_Transcript_Concall_01082026.pdf)
- 2026-08-06 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20260806_145641577.xml)
- 2026-08-03 — Generic Announcement: Divi's Laboratories Limited published its unaudited financial results for the quarter ended June 30, 2026, on August 2, 2026, in the Financial Express and Andhra Prabha newspapers. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_03082026121144_Intimation_of_Newspaper_Publication_Q1FY27.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, reporting consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. The board also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026114235_Outcome_BoardMeeting_01082026_DivisLabs.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited uploaded the audio recording of its Q1 FY27 earnings conference call, held on August 01, 2026, to its website. This disclosure is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026154417_Intimation_Q1FY27EarningsCall_AudioRecording.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, reporting consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. The board also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026113144_Outcome_BoardMeeting_01082026_DivisLabs.pdf)
- 2026-08-01 — Official Filing: Divi's Laboratories Limited announced the appointment of two senior management personnel on August 1, 2026, following a board meeting. Mr. B. Vara Prasad was appointed General Manager (Engineering Purchase), and Mr. J. Srinivasa Rao was appointed General Manager (Raw Materials Purchase). Both individuals have extensive experience in the pharmaceutical procurement sector.
- 2026-07-31 — Generic Announcement: Divi's Laboratories Limited announced the cessation of two Senior Management Personnel, Mr. L. Ramesh Babu (Vice President, Procurement) and Mr. D. Madhu Babu (Vice President, Projects), due to retirement. Their cessation will be effective from the close of business hours on July 31, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_31072026091128_Regulation30Intimation31072026.pdf)

## News and market events

- 2026-11-07 — The Hindu: **Divi's Lab net profit surges 63% to ₹1,127 cr in Q2** — Divi's Laboratories reported a 63.57% surge in second-quarter net profit to ₹1,127 crore, driven by a 35.39% revenue increase to ₹3,676 crore. This strong quarterly performance contrasts with a 35.39% decline in the company's half-year net profit, which fell to ₹2,029 crore from ₹2,568 crore in the corresponding period of the previous fiscal year. — [Source](https://www.thehindubusinessline.com/companies/divis-lab-net-profit-surges-63-to-1127-cr-in-q2/article71677850.ece)
- 2026-11-07 — Economic Times: **Divi's Labs Q2 Results: PAT surges 64% YoY to Rs 1,127 crore; revenue jumps 35%** — Divi's Laboratories reported a 63.6% year-on-year surge in consolidated profit after tax to Rs 1,127 crore for the September quarter of FY27, driven by a 35.4% increase in operational revenue to Rs 3,676 crore. The pharmaceutical company also recorded consolidated total income of Rs 3,770 crore for the quarter, while its first-half PAT rose to Rs 2,029 crore from Rs 1,234 crore in the previous fiscal period. Ahead of the results announcement, Divi's Labs shares settled at Rs 10,305 on the BSE, reflecting a 1.53% gain. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/divis-labs-q2-results-pat-surges-64-yoy-to-rs-1127-crore-revenue-jumps-35/articleshow/135632058.cms)
- 2026-10-27 — BUSINESSTODAY: **Nilima Prasad Divi on where Divi’s spends, invests, and expands** — Anticipating risks before they disrupt operations and ensuring commercial decisions support long-term growth are central to leadership in pharmaceutical manufacturing. — [Source](https://www.businesstoday.in/magazine/profile/story/nilima-prasad-divi-on-where-divis-spends-invests-and-expands-564096-2026-10-27)
- 2026-10-19 — CNBC-TV18: **Divi's Laboratories shares gain as weight loss drug receives EU panel backing** — Analysts believe Divi's Laboratories is likely to be the intermediate supplier of orforglipron for weight loss. The stock may see a reaction in today's trading session. — [Source](https://www.cnbctv18.com/market/divis-laboratories-share-price-weight-loss-drug-eu-panel-backing-orforglipron-foundayo-q2-impact-20014579.htm)
- 2026-10-19 — Economic Times: **Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players** — India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/indias-pharmaceutical-companies-to-report-mixed-results-as-domestic-growth-offsets-pricing-pressures/articleshow/135037267.cms)
- 2026-10-05 — MONEYCONTROL: **Novo's manufacturing pivot reinforces peptide CDMO case; Divi's is Macquarie's top Indian pick** — Novo Nordisk, Divi's Labs — [Source](https://www.moneycontrol.com/news/business/markets/novo-s-manufacturing-pivot-reinforces-peptide-cdmo-case-divi-s-is-macquarie-s-top-indian-pick-14044745.html)
- 2026-09-28 — CNBC-TV18: **Sensex closes over 1,000 points lower: 5 reasons behind today's market fall** — All four frontline indices closed nearly 2% lower, with the Nifty Bank emerging as the biggest underperformer. Rising crude continued to weigh on the market, with seven Nifty stocks closing at their 52-week lows. — [Source](https://www.cnbctv18.com/market/sensex-closes-over-1000-points-lower-5-reasons-behind-todays-market-fall-20000056.htm)
- 2026-09-25 — Mint: **Indian stock market slides, but 28 Nifty 500 stocks hit fresh 1-year highs this week; MCX, PVR Inox among them** — The Nifty 50 index experienced its biggest decline since 2020, down 0.88% over the last week. Despite a wider market sell-off, stocks like Welspun Corp and Zydus Lifesciences reached new peaks, highlighting selective investor interest amid high crude oil prices and global bond yield fluctuations. — [Source](https://www.livemint.com/market/stock-market-news/indian-stock-market-slides-but-28-nifty-500-stocks-hit-fresh-1-year-highs-this-week-mcx-pvr-inox-among-them-11790344289040.html)
- 2026-09-24 — Economic Times: **F&O Radar: Bull Call Spread strategy for Divi’s Laboratories this week** — Divi’s Laboratories remains in a strong uptrend after a multi-year breakout, with supportive momentum and options data pointing to further upside. Analysts see Rs 9,800 as a key hurdle and Rs 10,000 as the next potential level. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/fo-radar-bull-call-spread-strategy-for-divis-laboratories-this-week/articleshow/134455756.cms)
- 2026-09-18 — Economic Times: **Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August** — Capitalmind Flexi Cap Fund made five fresh additions and completely exited five stocks from its portfolio in August, while keeping its exposure unchanged in 27 stocks. The fund had 32 stocks across 17 sectors, with healthcare accounting for the largest allocation. Heres a look at the stocks added and exited, sector allocation and the funds performance since inception. — [Source](https://economictimes.indiatimes.com/mf/analysis/capitalmind-flexi-cap-fund-adds-divis-laboratories-bajaj-auto-and-3-other-stocks-in-august/articleshow/134328679.cms)
- 2026-09-17 — CNBC-TV18: **India’s highest-paid CEOs in FY26: Who took home the biggest pay packages** — Meet India’s highest-paid CEOs in FY26. From Persistent Systems' Sandeep Kalra crossing ₹388 crore to Angel One's Ambarish Kenghe posting a 10,000% spike, here are the 10 highest-paid business leaders in FY26 and their compensation packages. — [Source](https://www.cnbctv18.com/photos/business/indias-highest-paid-ceos-in-fy26-who-took-home-the-biggest-pay-packages-19993029.htm)
- 2026-09-08 — MONEYCONTROL: **Trade Spotlight: How should you trade Titagarh Rail Systems, AIA Engineering, Apollo Hospitals, Divis Labs, Blue Star, and others on September 8?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-titagarh-rail-systems-aia-engineering-apollo-hospitals-divis-labs-blue-star-and-others-on-september-8-14024785.html)
- 2026-09-01 — CNBC-TV18: **Symbiotec Pharmalab shares to list today; GMP signals 19% premium over IPO price** — If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988. — [Source](https://www.cnbctv18.com/market/symbiotec-pharmalab-share-price-ipo-listing-today-premium-discount-gmp-signals-issue-price-nse-bse-19980955.htm)
- 2026-08-24 — The Hindu: **Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon** — The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times — [Source](https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-sees-subscription-at-070x-by-mid-afternoon/article71384017.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-15 — The Hindu: **India Inc throws up a pleasant surprise in Q1 as compared to gloom at the start of the quarter** — India Inc's Q1 performance shows strong revenue growth, defying initial gloom, despite challenges from rising input costs. — [Source](https://www.thehindubusinessline.com/portfolio/india-inc-throws-up-a-pleasant-surprise-in-q1-as-compared-to-gloom-at-the-start-of-the-quarter/article71350303.ece)
- 2026-08-10 — CNBC-TV18: **Why Hyundai, Ashok Leyland and ICICI Bank are among Macquarie's top picks** — Sandeep Bhatia of Macquarie Capital breaks down this quarter's earnings surprise across large and small caps, his top picks in autos and private banking, and a possible rotation between technology and power stocks tied to global AI valuations over the next 18 months. — [Source](https://www.cnbctv18.com/market/why-macquarie-sandeep-bhatia-hyundai-ashok-leyland-icici-bank-india-next-winners-divis-labs-nestle-shriram-transport-rbi-artificial-intelligence-itc-19965333.htm)
- 2026-08-03 — The Hindu: **Sensex today | Stock Market Live: Sensex rises 600 pts, Nifty near 24,600; ITC, IndiGo lead gainers; Muthoot Finance down 10%; PMI Manufacturing slips to near 5-year low in July** — Sensex, Nifty, Stock Price Live Updates: The fresh week began on a positive note for Indian stocks, thanks to softer crude oil prices and stable global markets. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-3rd-august-2026/article71298312.ece)
- 2026-08-03 — CNBC-TV18: **Q1 Results LIVE Updates: Maruti, Persistent, IOC react to earnings; SBI Funds, UPL, DLF report today** — Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-maruti-sbi-mf-upl-dlf-ireda-ioc-dixon-persistent-muthoot-cams-escorts-ather-abb-divis-share-price-liveblog-19959998.htm)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty bulls set sights on 24,500 amidst crude cool-off, FCNR inflows** — Sensex Today | Stock Market Live Updates: The bulls, having ended the week with gains will now be eyeing two levels on the upside, 24,467, which is the recent swing high, and 24,500, which has been a psychological barrier, before the positional swing high of 24,601 could be retested. The Nifty Bank though, continues to struggle with 57,500 continuing to act as a hurdle. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-07-31 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty extends gains to 100 pts; PSU banks off lows** — Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-infosys-banks-tata-steel-swiggy-sun-pharma-mdl-bajaj-fin-share-price-liveblog-19958369.htm)

## Business profile

**Strategic vision:** Manufactures active pharmaceutical ingredients, intermediates, and nutraceuticals.

### Business segments
- **Generic APIs:** Divi's is a leading manufacturer of Generic APIs globally, offering over 30 commercial products and focusing on large-scale production.
- **Custom Synthesis:** Provides custom synthesis contract manufacturing services for APIs and intermediates to large pharmaceutical companies, handling high-potency compounds and high-energy reactions.
- **Nutraceuticals:** Supplies a comprehensive range of carotenoids and market-targeted vitamins for the nutritional, pharmaceutical, food/beverage, and feed industries.

### Competitive strengths
- Expertise in handling high-potency compounds and executing high-energy reactions.
- Large-scale production capabilities for APIs.
- Established global supply chain with long-term partnerships.
- Adherence to stringent global regulatory standards.

## Related stocks

- [Sun Pharmaceutical Industries Limited (Healthcare)](https://faxioms.com/stocks/sunpharma) — +1.69%
- [Torrent Pharmaceuticals Limited (Healthcare)](https://faxioms.com/stocks/torntpharm) — +0.85%
- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/divislab
Markdown representation: https://faxioms.com/stocks/divislab?render=md